Navigation Links
Valeant Announces Increase to Securities Repurchase Program
Date:5/28/2009

ALISO VIEJO, Calif., May 28 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) announced today that its board of directors has authorized the repurchase of an additional $300 million of its outstanding convertible debt or common stock under the securities repurchase program approved in October 2008. This repurchase authorization raises the aggregate repurchase authorization to $500 million from $200 million over a period ending May 2011. To date, the Company has repurchased $139 million in total of its convertible debt and its common stock out of the $500 million authorized under the securities repurchase program.

Under the securities repurchase program, the Company may repurchase its securities from time to time on the open market, in privately negotiated transactions pursuant to tender offers or otherwise, including pursuant to one or more trading plans, at times and in amounts as the Company deems appropriate. The amount of securities to be purchased and the timing of purchases may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements and alternate investment opportunities. The repurchase program may be modified or discontinued at any time.

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including, but not limited to, statements regarding the securities repurchase program. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to the market conditions, the Company's ability to execute purchases under the securities repurchase program and other risks and uncertainties as set forth under the caption "Risk Factors" in the Company's most recent annual or quarterly report filed with the SEC, which factors are incorporated herein by reference. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this release or to reflect actual outcomes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
7. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
10. Valeant to Acquire Polish Dermatology Company
11. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , ... May 31, 2016 , ... TeaZa® Energy, ... herbal energy pouches, on World No Tobacco Day . The new flavor—Tropical ... locations later on this summer. , The new flavor is best described as ...
(Date:5/31/2016)... ... May 31, 2016 , ... Dr. Charles A. Ditta attained ... New Jersey in the class of 1986, where he graduated in the top ten ... current location in Livingston since 1989. He has been a member in good standing ...
(Date:5/31/2016)... ... May 31, 2016 , ... CURE ... patients with cancer, has added Cancer and Careers to its ... timely content on continuing successful careers while fighting cancer. , As partners, both ...
(Date:5/30/2016)... Viejo, California (PRWEB) , ... May 30, 2016 ... ... are easy to use inside of FCPX," said Christina Austin - CEO of ... created exclusively for use within Final Cut Pro X. Choose from abstract transitions ...
(Date:5/30/2016)... Lewisville, Texas (PRWEB) , ... May 30, 2016 , ... ... at 7 am in Plano, located at 3960 Legacy Drive, Plano, TX and is ... the Plano Chamber of Commerce followed by a medical open house. The Jasper High ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 2016 , Isansys  Lifecare, a new ... Status Engine wireless patient monitoring platform, as it ships more ... Germany , Scotland and ... generation system, launched earlier this year, is now being used ... , This new technology significantly enhances the user ...
(Date:5/30/2016)... 30, 2016 Transparency Market Research ... Visualization Systems Market - Global Industry Analysis, Size, Share, ... the report, the global advanced (3D/4D) visualization systems market ... is anticipated to expand at a CAGR of 6.4% ... in 2024. Advanced (3D/4D) visualization systems have ...
(Date:5/30/2016)... , May 30, 2016 ... to reach USD 7.3 billion by 2024, according ... Inc. The increasing natality rate, the growing malnutrition ... as cancer and gastro-intestinal tract diseases are expected ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
Breaking Medicine Technology: